[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337669-105":59,"doc-detail-337669-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tak1-inhibition-leads-to-ripk1-dependent-apoptosis-in-immune-activated-cancers","TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers","","Glioblastoma multiforme (GBM) is a highly malignant adult brain tumor with poor prognosis and limited therapeutic options, including late detection, intratumoral heterogeneity, and weak responses to cytotoxic treatments. Evidence links resistance and recurrence to persistent glioblastoma stem cells (GSCs), motivating identification of molecular vulnerabilities that sustain GSC survival. Using unbiased CRISPR screening, the study identifies TAK1 as a selective dependency in GSCs and other cancers with immune-signaling activation and mesenchymal subtype features, enabling prediction of sensitivity to TAK1 inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tak1-inhibition-leads-to-ripk1-dependent-apoptosis-in-immune-activated-cancers/337669/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tak1-inhibition-leads-to-ripk1-dependent-apoptosis-in-immune-activated-cancers/337669.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are glioblastoma stem cells important for long-term treatment success in GBM?","Question",{"text":112,"@type":113},"Therapy resistance and tumor recurrence are attributed to persistence of glioblastoma stem cells within patient tumors. Eliminating these plastic tumor-initiating cells is considered key to durable therapeutic success.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the immune signal TNFα connect to TAK1 and RIPK1 in this study’s background?",{"text":117,"@type":113},"TNFα activates NF-κB and MAPK via TNF receptor signaling and can also trigger apoptosis through caspase pathways involving RIPK1. TAK1 is described as a regulator of cell fate outcomes following TNF receptor stimulation.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental strategy was used to identify TAK1 as a dependency?",{"text":121,"@type":113},"Unbiased CRISPR/Cas9 drop-out screens were performed using a focused sgRNA library targeting epigenetic regulators in two GSC lines, followed by abundance measurements over time to identify depleted sgRNAs and define hit criteria.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337669,1790100407,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers  \nHelene Damhofer1,2,3, Tülin Tatar1,3, Benjamin Southgate4, Scott Scarneo5,6, Karl Agger3, Daria Shlyueva2,3, Lene Uhrbom 7  \nGillian M. Morrison4, Philip F. Hughes5,6, Timothy Haystead5,6, Steven M. Pollard 4 and Kristian Helin 1,2,3 ✉ ,  \n© The Author(s) 2024  \nINTRODUCTION  \nGlioblastoma multiforme (GBM) is the most common and malignant form of primary adult brain tumors with a dismal prognosis [1]. Therapeutic options are limited as GBMs are highly inﬁltrative to the surrounding normal brain parenchyma precluding complete surgical removal. Moreover, GBMs are often detected late, display substantial inter- and intra-tumoral heterogeneity and respond poorly to most cytotoxic treatment regimens [2, 3] .  \nCompelling evidence suggests that therapy resistance and subsequent tumor recurrence in GBM is attributed to the persistence of a population of glioblastoma stem cells (GSCs) within patient tumors. Elimination of these plastic tumor-initiating cells is considered key to achieving long-lasting therapeutic success [4] . Unfortunately, therapies targeting GSCs have been elusive, and are hampered by genetic heterogeneity. A deeper understanding of the molecular pathways maintaining GSC survival is therefore required to ﬁnd novel vulnerabilities that can be exploited therapeutically either across or within the distinct tumor subtypes.  \nLarge-scale genomics and transcriptomics analyses have led to the classiﬁcation of GBM tumors and GSCs into three main molecular subtypes: classical, proneural, and mesenchymal [5, 6] . Patients with the mesenchymal subtype have the poorest survival rates, display increased immune cell inﬁltration, and show the strongest degree of resistance to chemo- and radiation therapy making it the subtype with the most pressing need for additional  \ntreatment options [6, 7] . However, multiregional sampling and single-cell sequencing studies have shown that individual GBM tumors contain mixtures of tumor cells from multiple transcriptional subtypes and cellular states display a high degree of plasticity with the most prominent example of a proneural-tomesenchymal transition occurring in 59% of patients upon disease relapse following therapy [6, 8] . This phenotypic plasticity in GBMis thought to be one of the main drivers of failure to respond to current treatment modalities.  \nBoth cell intrinsic factors such as mutations in tumor suppressors NF1 and PTEN as well as external stimuli from the tumor microenvironment contribute to the acquisition of mesenchymal subtype and stem cell features in GBM [5, 6, 9] . One of the key external signals regulating this transition is tumor necrosis factor alpha (TNFα), which through binding to the TNF receptor activates NF-κB and MAPK signaling pathways and consequently transcription of inﬂammatory and survival genes [10] . Conversely, TNFα can also trigger apoptosis via activation of Caspase-8 and receptor-interacting serine/threonine kinase 1  \n(RIPK1); and TGFβ activated kinase 1 (TAK1) is an important regulator in controlling cell fate outcomes upon TNF receptor stimulation [11–13] .  \nHere using unbiased CRISPR screening, we report on the identiﬁcation of TAK1 as a novel, selective dependency in GSCsand other cancers with activated immune-signaling pathway and mesenchymal subtype features. We show that a transcriptional sensitivity signature can be employed to successfully predict  \n1Division of Cancer Biology, The Institute of Cancer Research, London, UK. 2Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark. 4Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK. 5Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA. 6EydisBio Inc., Durham, NC, USA.","cbCainSRCKqiPQrc","https://ap.wps.com/l/cbCainSRCKqiPQrc","pdf",6970795,17,"English","# Introduction\n## GBM prognosis, heterogeneity, and stem cell-driven resistance\n## Molecular subtype transitions and immune signaling\n# Results\n## TAK1 as a selective dependency in GSCs\n## CRISPR/Cas9 screening approach and hit selection","[{\"question\":\"Why are glioblastoma stem cells important for long-term treatment success in GBM?\",\"answer\":\"Therapy resistance and tumor recurrence are attributed to persistence of glioblastoma stem cells within patient tumors. Eliminating these plastic tumor-initiating cells is considered key to durable therapeutic success.\"},{\"question\":\"How does the immune signal TNFα connect to TAK1 and RIPK1 in this study’s background?\",\"answer\":\"TNFα activates NF-κB and MAPK via TNF receptor signaling and can also trigger apoptosis through caspase pathways involving RIPK1. TAK1 is described as a regulator of cell fate outcomes following TNF receptor stimulation.\"},{\"question\":\"What experimental strategy was used to identify TAK1 as a dependency?\",\"answer\":\"Unbiased CRISPR/Cas9 drop-out screens were performed using a focused sgRNA library targeting epigenetic regulators in two GSC lines, followed by abundance measurements over time to identify depleted sgRNAs and define hit criteria.\"}]","TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers | PDF",1790020047,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43bd2d55b1778765e38f1e094e22bcd9.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bdedf3b196836d73acb1065f8d37616.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef76d84fe997a0e3a8dd2f72f0cec496.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b782afefdc166a3c5d97b5c76431872d.webp",980,1301]